US EditionTaiwan's ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant Patients
- ACRO Biomedical, a Taiwan company, announced on April 14, 2025, that Taiwan MOHW approved its ABCcolla matrix.
- A global shortage of transplantable corneas exists, as demand rises with an aging population.
- ABCcolla is designed to treat corneal damage from trauma, melting, or infections, offering a new treatment option.
- Dr. DJ Hsieh stated their vision addresses the shortage of tissues, ensuring timely corneal transplant treatment.
- The approval marks a key advance, as ACRO aims to reduce reliance on donated corneas and improve patient care.
Insights by Ground AI
Does this summary seem wrong?
60 Articles
60 Articles
All
Left
8
Center
17
Right
6
Taiwan's ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant Patients
KAOHSIUNG, April 14, 2025 /PRNewswire/ -- Taiwan – ACRO Biomedical Co., Ltd. (TWSE: 6748) announced today that its ABCcolla® Collagen Ophthalmic Matrix has received regulatory approval from Taiwan's Ministry of Health and Welfare (MOHW), with registration number: MOHW Medical Device…
Coverage Details
Total News Sources60
Leaning Left8Leaning Right6Center17Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 26%
C 55%
R 19%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
